We are live on
!
Find out more
AVA
Atlas Venture Advisors Portfolio holdings
AUM
$122M
1-Year Est. Return
26.28%
This Fund
S&P 500
This Quarter
Est. Return
-37.2%
1 Year Est. Return
-26.28%
3 Year Est. Return
-22.79%
5 Year Est. Return
-46.44%
10 Year Est. Return
–
AUM
$189M
AUM Growth
–
Cap. Flow
+$233M
Cap. Flow
% of AUM
122.8%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBLK
Carbon Black, Inc. Common Stock
CBLK
|
+$161M |
| 2 |
Larimar Therapeutics
LRMR
|
+$28.8M |
| 3 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
+$28.7M |
| 4 |
Viridian Therapeutics
VRDN
|
+$12.1M |
| 5 |
Snap
SNAP
|
+$1.59M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 69.58% |
| 2 | Healthcare | 29.71% |
| 3 | Communication Services | 0.71% |
Similar funds
RCWM
CCM
SO
MAM
PLC
VAM
TCM
NFGH
Atlas Venture Advisors's Q4 2018 Portfolio in Review
Q4 2018 is the first quarter with a 13F filing on record for Atlas Venture Advisors, which disclosed 5 positions worth $189M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Carbon Black, Inc. Common Stock: 9,823,103 shares worth $132M.
By sector, the portfolio is most concentrated in Technology at 70% of assets, followed by Healthcare and Communication Services.
- Atlas Venture Advisors's largest Q4 2018 buy was Carbon Black, Inc. Common Stock: 9,823,103 shares worth $132M.
- Atlas Venture Advisors's ten largest holdings make up 100% of its $189M portfolio in Q4 2018.
- Atlas Venture Advisors disclosed 5 positions in Q4 2018, its first 13F filing on record.
Based on Atlas Venture Advisors's 13F filing for Q4 2018, filed 8 Feb 2019.